PharmaTher To Raise $10.0 Million Via Institutional Investor Financing

PharmaTher Holdings (CSE: PHRM) this morning indicated that the company has secured a financing with institutional investors. The firm will be raising C$10.0 million via a financing conducted exclusively by H.C. Wainwright.

The financing will see the company sell a total of 15.6 million units of the company price at $0.64 per each, with each unit containing one common share and one common share purchase warrant. Each warrant, priced at $0.80 per share, is valid for a period of five years from the date of issuance.

Proceeds from the financing are to be used for the development of the firms microneedle patch, its ketamine product, and general working capital.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

The financing is currently slated to close September 28, 2021.

PharmaTher Holdings last traded at $0.80 on the CSE.


Information for this briefing was found via Sedar and the companies mentioned. PharmaTher Holdings is a former client of The Deep Dive. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Tungsten Went 6X. I Went to See the Deposit Time Forgot | DD-on-the-GO! – Rackla Metals Inc

The World’s Largest Undeveloped Gold Project Nears a Deal | Rudi Fronk – Seabridge Gold

One of the World’s Biggest Copper Mines Could Reopen Just to Shut Down | First Quantum

Recommended

First Majestic Produces 3.4 Million Ounces of Silver in Q3 2026, Jerritt Canyon Restart Remains on Track

Altamira Gold Drills 134 Metres of 0.5 g/t Gold at Maria Bonita, Hole Ends in Mineralization

Related News

Pharmather Files For Orphan Drug Status For Use Of Ketamine Against Postherpetic Neuralgia

Pharmather Inc (CSE: PHRM) this morning announced that it has filed for orphan drug status...

Tuesday, October 27, 2020, 08:42:25 AM

PharmaTher Files Patent For Use Of Ketamine In Type 2 Diabetes, Obesity

PharmaTher Holdings (CSE: PHRM) has expanded its patent portfolio. The company this morning announced the...

Tuesday, April 27, 2021, 07:54:44 AM

PharmaTher To Commence Phase 2 Clinical Study On Ketamine In Q2 2021

Pharmather Inc (CSE: PHRM) is successfully progressing on the development of its proposed phase 2...

Thursday, February 4, 2021, 08:28:04 AM

Pharmather: Combining Artificial Intelligence With Psychedelics For Novel Drug Discovery

Newscope Capital, whom is currently doing business as Pharmather (CSE: PHRM) is the latest firm...

Monday, October 12, 2020, 03:47:00 PM

PharmaTher Files With FDA For Orphan Drug Designation In Use Of Ketamine For ALS

PharmaTher Holdings (CSE: PHRM) this morning announced that it has filed with the US FDA...

Tuesday, May 25, 2021, 09:00:24 AM